GFAP and Alzheimer disease: AD and DS-AD COVID-19 negative (COVID-) cases exhibited an increase in the density of GFAP labeled cells, with shorter, stubbier processes indicative of an inflammatory glial-induced response to the AD pathology (Fig. 4a5, b5, b8).